Cartesian Therapeutics (RNAC) Accumulated Depreciation (2015 - 2016)
Cartesian Therapeutics (RNAC) posted quarterly Accumulated Depreciation of $3.3 million for Q2 2016, up 13.32% quarter-over-quarter from $2.9 million in Q4 2015.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Accumulated Depreciation (2015 - 2016) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Accumulated Depreciation for 2 consecutive years, with $3.3 million the latest figure, recorded in Q2 2016.
- In Q2 2016, Accumulated Depreciation changed N/A year-over-year to $3.3 million; the TTM figure through Jun 2016 stood at $3.3 million (changed N/A YoY), while the FY2015 annual figure was $2.9 million, changed N/A from the prior year.
- Accumulated Depreciation improved to $3.3 million in Q2 2016 per RNAC's latest filing, from $2.9 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $3.3 million in Q2 2016 and bottomed at $2.9 million in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - |